These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

314 related items for PubMed ID: 32456317

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).
    Borgmann H, Lallous N, Ozistanbullu D, Beraldi E, Paul N, Dalal K, Fazli L, Haferkamp A, Lejeune P, Cherkasov A, Gleave ME.
    Eur Urol; 2018 Jan; 73(1):4-8. PubMed ID: 28851578
    [Abstract] [Full Text] [Related]

  • 4. Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis.
    Mori K, Mostafaei H, Pradere B, Motlagh RS, Quhal F, Laukhtina E, Schuettfort VM, Abufaraj M, Karakiewicz PI, Kimura T, Egawa S, Shariat SF.
    Int J Clin Oncol; 2020 Nov; 25(11):1892-1900. PubMed ID: 32924096
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Enzalutamide for the treatment of nonmetastatic castration-resistant prostate cancer.
    Altavilla A, Casadei C, Lolli C, Menna C, Ravaglia G, Gurioli G, Farolfi A, Brighi N, Conteduca V, Burgio SL, Schepisi G, Rossi L, Gargiulo S, Lisotti I, De Giorgi U.
    Expert Opin Pharmacother; 2020 Dec; 21(17):2091-2099. PubMed ID: 32783772
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Perspectives on the current and emerging chemical androgen receptor antagonists for the treatment of prostate cancer.
    Dellis AE, Papatsoris AG.
    Expert Opin Pharmacother; 2019 Feb; 20(2):163-172. PubMed ID: 30462924
    [Abstract] [Full Text] [Related]

  • 13. ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer.
    Fizazi K, Albiges L, Loriot Y, Massard C.
    Expert Rev Anticancer Ther; 2015 Feb; 15(9):1007-17. PubMed ID: 26313416
    [Abstract] [Full Text] [Related]

  • 14. Androgen receptor splice variants in the era of enzalutamide and abiraterone.
    Nakazawa M, Antonarakis ES, Luo J.
    Horm Cancer; 2014 Oct; 5(5):265-73. PubMed ID: 25048254
    [Abstract] [Full Text] [Related]

  • 15. Combination therapy with novel androgen receptor antagonists and statin for castration-resistant prostate cancer.
    Nakayama H, Sekine Y, Oka D, Miyazawa Y, Arai S, Koike H, Matsui H, Shibata Y, Suzuki K.
    Prostate; 2022 Feb; 82(3):314-322. PubMed ID: 34843630
    [Abstract] [Full Text] [Related]

  • 16. Resistance to second-generation androgen receptor antagonists in prostate cancer.
    Schmidt KT, Huitema ADR, Chau CH, Figg WD.
    Nat Rev Urol; 2021 Apr; 18(4):209-226. PubMed ID: 33742189
    [Abstract] [Full Text] [Related]

  • 17. Mechanisms of enzalutamide resistance in castration-resistant prostate cancer and therapeutic strategies to overcome it.
    Wang Y, Chen J, Wu Z, Ding W, Gao S, Gao Y, Xu C.
    Br J Pharmacol; 2021 Jan; 178(2):239-261. PubMed ID: 33150960
    [Abstract] [Full Text] [Related]

  • 18. Targeting the androgen receptor signaling pathway in advanced prostate cancer.
    Chung C, Abboud K.
    Am J Health Syst Pharm; 2022 Jul 22; 79(15):1224-1235. PubMed ID: 35390118
    [Abstract] [Full Text] [Related]

  • 19. Comparative efficacy of second-generation androgen receptor inhibitors for treating prostate cancer: A systematic review and network meta-analysis.
    Chen X, Wang Q, Pan Y, Wang S, Li Y, Zhang H, Xu M, Zhou H, Liu X.
    Front Endocrinol (Lausanne); 2023 Jul 22; 14():1134719. PubMed ID: 36967752
    [Abstract] [Full Text] [Related]

  • 20. Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor.
    Coleman DJ, Van Hook K, King CJ, Schwartzman J, Lisac R, Urrutia J, Sehrawat A, Woodward J, Wang NJ, Gulati R, Thomas GV, Beer TM, Gleave M, Korkola JE, Gao L, Heiser LM, Alumkal JJ.
    Oncotarget; 2016 Jun 28; 7(26):40690-40703. PubMed ID: 27276681
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.